A Pulitzer Prize-winning journalism website that fact-checks politicians’ claims has waded into the controversy over whether President Biden raised insulin prices by freezing a 340B-related Trump administration regulation.
On Feb. 11, the Poynter Institute’s PolitiFact site rated U.S. Senate
…
Drug manufacturer Bausch Health last week said on the U.S. Health Resources and Services Administration website that its branded NDCs “will once again be available at the 340B ceiling price” through AmeriSourceBergen Corp. (ABC) “for eligible 340B purchases made by
…
The ability to generate profits through the 340B program prompts hospitals to buy physician practices and shift delivery of care to more costly hospital outpatient settings, driving up drug costs for patients and employers, Pharmaceutical Research and Manufacturers of America
…
A federal district judge in Oakland, Calif., on Tuesday expressed doubt that she had jurisdiction to require the U.S. Health and Human Services Department (HHS) to make drug manufacturers repay 340B hospitals for drug discounts that the companies have declined
…The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).
The language
…Three national hospital groups and three hospitals yesterday asked the U.S. Supreme Court to overturn a federal appeals court’s 2-1 July 2020 decision that the nearly 30 percent cut since 2018 in 340B hospitals’ drug reimbursement under the hospital outpatient
…
The American Hospital Association (AHA) last week told the U.S. Centers for Medicare & Medicaid Services (CMS) that insurance company UnitedHealthcare’s (UHC) specialty pharmacy coverage policies “undermine the intent of the 340B program” and should be disallowed.
In a Feb.
…
The Biden administration late yesterday told the U.S. Supreme Court that, due to the change in the presidency, the federal government has changed its main position in the lawsuit over the Affordable Care Act’s (ACA) constitutionality. The government now says
…
Drug manufacturer Glaxo Smith Kline (GSK) yesterday notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website that it is offering refunds for overcharges on about two dozen NDCs during the first quarter of 2019.
In
…*Sign up for news summaries and alerts from 340B Report
